The Invesco Biotechnology & Genome ETF (PBE) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market. What ...

The Invesco Biotechnology & Genome ETF (PBE) was launched on June 23, 2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the ...

This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...

The ARK Genomic Revolution ETF remains a "Buy" as it beats SPY/XLV, shows bullish breakout signals, and targets $42. Learn more about the fund.

Cathie Wood's ARK sold $2.78M Twist Bioscience, bought Tempus AI & WeRide Jan 26. Full breakdown of ARK Invest's latest AI ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

On Thursday, Jan. 22, 2026, Cathie Wood-led Ark Invest bought $2.4 million in Tempus AI and WeRide while selling $1.6 million ...